Introduction
Venousthromboembolism(VTE),includingdeep vein thrombosis (DVT) and pulmonary embolism,isacommoncomplicationofcancerandits treatmentandoccursmorefrequentlyinpatients withcancerthaninpatientswithoutit.Patients withcancerhaveanannualizedriskofVTE6to12 timeshigherthanthosewithoutcancer. 1 Among patients with cancer,VTE is strongly associated with reduced survival, 2 and thromboembolismisthesecondleadingcauseofdeathamong outpatients who are receiving cancer therapy. 1 Clinical trial data have demonstrated that anticoagulationtherapyforpreventionortreatment ofVTE in patients with cancer, especially lowmolecular-weight heparins (LMWHs), prevents morbidityandmaydecreasemortality. 3 Conclusions:Evidence suggests that LMWH for 3 to 6 months is the preferred strategy for most cancer patients who have experienced a thromboembolic event and for hospital inpatients, but this is often not implemented in practice. Concerns about adherence with injectable therapy should not prevent use of these agents. Pharmacists should assess cancer patients for their risk of VTE and should advocate for optimal VTE pharmacotherapy as appropriate. If LMWH is the preferred agent, on the basis of the evidence, the pharmacist should educate the patients appropriately and work with the prescriber to ensure best care. Can Pharm J 2012;145:24-29.
anticoagulanttherapy,VTEoftengoesunrecognizedandmaybetreatedsuboptimally.Pharmacistsarewellpositionedtoaidinenhancingthe managementofcancerpatientswhohaveorare atriskofVTE.
The purpose of this review is to provide an overview of the epidemiology of thrombosis in patients with cancer, to highlight evidence pertaining to its treatment and prevention in this populationandtosuggesthowpharmacistsmay playaroleinimprovingthecareofpatientswith cancerandVTE.
Methods
A literature review was conducted by searching MEDLINE,EMBASEandInternationalPharmacy AbstractsforarticlespublishedfromJanuary1995 toAugust2010thatexaminedclinicaloutcomes relatedtothrombosisandcancerandthepharmacist'srole.OnlineformulariesforCanadianprovinceswerealsoreviewedtodeterminecoveragefor LMWHusedforthisindication.
Results

DVT and PE
Patientswithcancerhaveasignificantlygreater riskofmorbidityandmortalityfromthromboembolism relative to patients without cancer. Overall,15%ofpatientswithcancerwillexperi-encesymptomaticDVTatsomepoint,butthis rateunderestimatestheimportanceoftheprob-lemwhenoneconsidersthatfully50%ofcancer patientsexperienceasymptomaticDVTandthat post-mortemstudieshaveshownaDVTriskof 50%atautopsy,makingVTEapossiblecauseof deathinthesecases. 4 Infact,1in7cancerpatients undergoing treatment in hospital dies because ofpulmonaryembolism. 5 Amongpatientswith cancer,theriskofdeathwithin6monthsofaVTE eventis94%,3timestheriskinpatientswithout cancer. 6 AlthoughmostVTEeventsarenotfatal, they cause significant morbidity through postthromboticsyndrome,pain,possibledruginteractionsandincreasedreadmissiontohospital. 2 
Risk of thrombosis
Prophylaxis
The frequency ofVTE in cancer patients being treated in hospital ranges from 0.6% to 5.4%. 9 Among medical inpatients with cancer, rates of VTE are lower with prophylaxis using LMWH, ratherthanunfractionatedheparin(UFH)orplacebo,withoutsignificantlyhigherratesofmajor bleeding. 10 Three large randomized controlled trials demonstrated the efficacy of enoxaparin, dalteparinandfondaparinux,respectively,inpre-ventingVTEinmedicalpatientsbeingtreatedin hospital(Table1). [11] [12] [13] Ineachofthesetrials,data were reported for nonrandomized cancer sub-
•VTEiscommoninpatientswithcancerand resultsinsignificantmorbidityandmortality.
•Avarietyofanticoagulantsmaybeusedto preventVTEinhospitalizedpatientswith cancer.
•Extended-durationLMWHtherapy(3-6 months)hasdemonstratedsuperiorout-comesincancerpatientswithanactiveVTE eventascomparedtooralanticoagulants. 15 Thedataclearly demonstratetheefficacyandsafetyofLMWHfor prophylaxisofVTEinthispopulationandtherisk ofVTEeventsdeclinesbyabout50%withprophylaxis. 16 Prophylaxis in ambulatory patients Preliminary data from randomized controlled trialsinvolvingambulatorypatientswithcancer are conflicting. This, in combination with the known risk of bleeding in patients with cancer, suggeststhatprophylaxisislikelynotwarranted in the majority of ambulatory cancer patients giventhebenefittoriskratio.Conversely,throm-boprophylaxiswithafixed,lowdoseofwarfarin (1-2mg/day)oraLMWHmaybewarrantedfor patientswithmultiplemyelomawhoarereceiving thalidomide-orlenalidomide-basedcombination therapy. 17 Furtherdataarerequiredforthispopulation.
Key points
Treatment of VTE
Use of anticoagulants to treat VTE in cancer patientsisassociatedwithbothsubstantialbenefitsandhighratesofcomplications.Mostcancer patients with VTE require anticoagulation, but anticoagulationmaybewithheldforasmallsubsetofpatientsifthereisnotherapeuticadvantage (e.g.,forpatientswithahighriskofcomplications ofVTEtreatment,thosewhoseexpectedsurvival isshort,thosewithnoplannedoncologicalinterventionandthoseforwhomnopalliativebenefit isanticipated). SeveraltrialshaveassessedtreatmentofVTE with LMWH in patients with cancer (summar-izedinTable2).Thelargestofthese,theCLOT trial,compareddalteparinwithvitaminKantagonists. 18 Dalteparin was associated with a 52% relativeriskreduction(RRR)intheincidenceof recurrentVTEduringthe6monthsoffollow-up. Therewerenosignificantdifferencesbetweenthe 2treatmentgroupsintheratesofmajorbleeding oranybleeding.TheCANTHANOXstudy,which was stopped early because of low recruitment, demonstrated a reduction in the primary end point(definedaseitherrecurrentVTEormajor bleedingorboth)withenoxaparintherapy(7vs 15patients,p=0.09). 19 Theendpointwasdriven 
Points clés
bymajorbleeding(whichoccurredin5patientsin theenoxaparinarmand12inthewarfarinarm). The3-armedONCENOXstudydemonstratedno differencesbetweentheenoxaparinandwarfarin groupsintermsofrecurrentVTE,majorbleeding ordeath;however,thesmallsamplesizeprecludes strongconclusions. 20 Tinzaparinwasmoreeffect-ivethanwarfarinfor200patientswithcancerin theLITEstudy. 21 Inthatstudy,tinzaparinreduced therateofrecurrentVTEbyabout50%,butthe differencewasnotstatisticallysignificant.There werenodifferencesinbleedingrates.
Guidelines
GiventheprevalenceandimpactofVTEinpatients with cancer, as well as the wealth of data demonstratingtheefficacyandsafetyofprophylaxis andtreatmentofVTEinthispopulation,several groups,includingtheAmericanSocietyofClin-icalOncology(ASCO), 9 theAmericanCollegeof ChestPhysicians, 22 theEuropeanSocietyforMed-icalOncology 23 andtheNationalComprehensive CancerNetwork, 24 havepublishedguidelinesfor cliniciansonthistopic(summarizedinTable3). AlthoughtheguidelinessupportuseofLMWH forVTEprophylaxisincancerpatientswhoare beingtreatedinhospital,anumberofcontraindicationsexist.Inparticular,theASCOguidelines 9 cite the following as relative contraindications: active uncontrollable bleeding; active cerebrovascularhemorrhage;dissectingorcerebralaneurysm;bacterialendocarditis,bacterialpericarditis oractivepepticorothergastrointestinalulceration;severe,uncontrolledormalignanthypertension; severe head trauma; and placement of an epiduralcatheter.
Discussion
Despite the data pertaining to the efficacy and safety of prophylaxis and treatment of VTEincancerpatients and several guidelines suggesting appropriate strategies, data from cohort studies suggest that only about half of patients eligible for appropriate therapy receiveit. 4, 17, 23 Inunderstandingthistreatment gap, it is important to consider various contributingfactors,includingwhetherpatientsare abletoadheretoorgainaccesstoavailableprophylacticortreatmentregimens.
Availabledatasuggestthatpatientsareableto adhere to the LMWH regimens and find them acceptable as treatment strategies. For example, adherencetodailyenoxaparintherapywas94% to97%intheONCENOXtrial,whichexceeded the 92.8% adherence for warfarin. 20 Lee et al. reportedthat78%ofeligiblepatientsintheCLOT studyfoundlong-termself-injectionofdalteparin acceptable. 18 In terms of accessibility, the various public drugplansacrossCanadaaredivergentinterms ofcoverageoftheseagents(Table4). [25] [26] [27] [28] [29] [30] [31] Despite recent evidence demonstrating the efficacyandsafetyofLMWHinthetreatmentof VTEinpatientswithcancer,vitaminKantagonists and UFH continue to be used in some set- 35 Regardlessoftheselectedantithrombotictherapy,pharmacistsareinapositiontoeducatepatients abouttheriskofVTE,theriskofbleedinganddirectionsforcareifsuchaneventoccurs.Theycanalso emphasizetheimportanceofadherencewiththerapy.Pharmacistsshouldalsoworkwiththepatient andothercaregiverstominimizetheimpactofdrug interactionsinvolvinganticoagulanttherapy.
Conclusions
PatientswithcancerareathighriskofVTE,which canresultinsignificantmorbidityandmortality. Recent evidence has demonstrated the value of anticoagulanttherapyandtheuseofLMWHsin thesepatients.AllprovincialdrugplansinCanadahaverecognizedthevalueofthistherapeutic approach and have made these agents available either on an open-listing basis or with specific criteria.Inaddition,utilizationoftheseagentsis acceptabletopatients.Giventheefficacyandsafety datapertainingtoLMWHandthechallengesof usingwarfarininpatientswithcancer,pharmacists arewellpositionedtoadvocatefortheapproach thatbestmeetspatients'needsandtoensurethat theselectedapproachisimplemented.n • Les pharmaciens peuvent jouer un rôle important dans la prévention et la prise en charge d'une thrombose. Ils sont tous en mesure d'informer les patients du risque de thromboembolie veineuse et de saignement, ainsi que de ce qu'il faut faire dans une telle situation. • Les pharmaciens peuvent expliquer aux patients les différences entre les anticoagulothérapies par voie orale et par injection, ainsi que la façon de maximiser les résultats de chacune d'elle. 
• Les pharmaciens peuvent collaborer avec les cliniciens et les patients pour s'assurer que les patients atteints de cancer et de thromboembolie veineuse reçoivent les traitements qui se sont avérés les plus efficaces.
Mise en pratique des connaissances
